TTI specializes in leveraging its patented rapid-acting, drug-specific, liquid sprayed-on transdermal delivery technology to develop effective alternative delivery systems for valued drugs. No other company can offer similar, consumer-friendly, dosing-flexible solutions.

The Company's platform technology, TDS® is a patented physio-chemical and mathematical process for designing a system capable of temporarily neutralizing the skin's barrier function, enabling delivery to or through the skin, to local tissues or to the whole body, of a very wide range of compounds with pharmaceutical or cosmetic value.

TDS® is a liquid, spray-on and patch-less technology.

By applying its platform TDS® technology, TTI develops delivery solutions for
major-market drugs that it believes:

• Offer new treatment options for difficult-to-medicate patients
• Minimize drug-drug interactions often associated with oral
......dosage forms
• Can get licensees quickly/inexpensively to market
• Can potentially extend the patent lives of highly-valued brands of
......collaborating licensees

The U.S. Patent & Trademark Office has granted TTI patents on its platform
technology and there appear to be no similar technologies.

TTI believes its platform technology holds enormous long-term clinical and
economic potential for treating millions of the industrial and developing world's
growing population who will increasingly look to drug therapy as a cost-contained
first line of attack.